These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1370692)

  • 1. Identification of B-cell antigenic sites on HIV-2 gp125.
    Mannervik M; Putkonen P; Rudén U; Kent KA; Norrby E; Wahren B; Broliden PA
    J Acquir Immune Defic Syndr (1988); 1992; 5(2):177-87. PubMed ID: 1370692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of monoclonal antibodies to human immunodeficiency virus type 2 envelope glycoproteins.
    Traincard F; Rey-Cuillé MA; Huon I; Dartevelle S; Mazié JC; Benichou S
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1659-67. PubMed ID: 7888225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2.
    Björling E; Chiodi F; Utter G; Norrby E
    J Immunol; 1994 Feb; 152(4):1952-9. PubMed ID: 8120399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.
    Björling E; Broliden K; Bernardi D; Utter G; Thorstensson R; Chiodi F; Norrby E
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6082-6. PubMed ID: 2068087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of neutralizing sites in the second variable and fourth variable region in gp125 and a conserved region in gp36 of human immunodeficiency virus type 2.
    Skott P; Achour A; Norin M; Thorstensson R; Björling E
    Viral Immunol; 1999; 12(1):79-88. PubMed ID: 10333245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of the V1/V2 region does not increase the accessibility of the V3 region of recombinant gp125.
    Sourial S; Nilsson C; Wärnmark A; Achour A; Harris RA
    Curr HIV Res; 2006 Apr; 4(2):229-37. PubMed ID: 16611061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenicity of linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein: synthesis, reoxidation and purification.
    Belhadj Jrad B; Bahraoui E
    J Pept Res; 1998 May; 51(5):370-85. PubMed ID: 9606017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity of antipeptide antibodies produced against V2 and V3 regions of the external envelope of human immunodeficiency virus type 2.
    Babas T; Benichou S; Guetard D; Montagnier L; Bahraoui E
    Mol Immunol; 1994 Apr; 31(5):361-9. PubMed ID: 8152439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein induced antibodies with different specificity.
    Jrad BB; Bahraoui E
    Mol Immunol; 1997; 34(16-17):1177-89. PubMed ID: 9566765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of linear antigenic sites in the envelope proteins of human immunodeficiency virus (HIV) type 2 and type 1.
    Norrby E; Putkonen P; Böttiger B; Utter G; Biberfeld G
    AIDS Res Hum Retroviruses; 1991 Mar; 7(3):279-85. PubMed ID: 1712215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of the HIV-2 envelope glycoprotein gp125.
    Campbell AP; Sykes BD; Norrby E; Assa-Munt N; Dyson HJ
    Fold Des; 1996; 1(2):157-65. PubMed ID: 9079375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic and immunogenic sites of HIV-2 glycoproteins.
    Chiodi F; Björling E; Samuelsson A; Norrby E
    Chem Immunol; 1993; 56():61-77. PubMed ID: 8452654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins.
    Marcelino JM; Barroso H; Gonçalves F; Silva SM; Novo C; Gomes P; Camacho R; Taveira N
    J Clin Microbiol; 2006 Feb; 44(2):607-11. PubMed ID: 16455923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.
    Cole KS; Alvarez M; Elliott DH; Lam H; Martin E; Chau T; Micken K; Rowles JL; Clements JE; Murphey-Corb M; Montelaro RC; Robinson JE
    Virology; 2001 Nov; 290(1):59-73. PubMed ID: 11883006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
    Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
    AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of human antibody-binding sites on the external envelope of human immunodeficiency virus type 2.
    de Wolf F; Meloen RH; Bakker M; Barin F; Goudsmit J
    J Gen Virol; 1991 Jun; 72 ( Pt 6)():1261-7. PubMed ID: 1710645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoprecipitation of human immunodeficiency virus type 2 glycoproteins by sera positive for human immunodeficiency virus type 1.
    Espejo RT; Uribe P
    J Clin Microbiol; 1990 Sep; 28(9):2107-10. PubMed ID: 2229392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human neutralizing human immunodeficiency virus type 2-specific Fab molecules generated by phage display.
    Björling E; von Garrelts E; Mörner A; Ehnlund M; Persson MAA
    J Gen Virol; 1999 Aug; 80 ( Pt 8)():1987-1993. PubMed ID: 10466795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.
    Silvera P; Flanagan B; Kent K; Rud E; Powell C; Corcoran T; Bruck C; Thiriart C; Haigwood NL; Stott EJ
    AIDS Res Hum Retroviruses; 1994 Oct; 10(10):1295-304. PubMed ID: 7848685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys.
    Andersson S; Mäkitalo B; Thorstensson R; Franchini G; Tartaglia J; Limbach K; Paoletti E; Putkonen P; Biberfeld G
    J Infect Dis; 1996 Nov; 174(5):977-85. PubMed ID: 8896498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.